Natixis Advisors LLC Sells 108,399 Shares of Edwards Lifesciences Corporation (NYSE:EW)

Key Points

• Natixis Advisors LLC reduced its holdings in Edwards Lifesciences Corporation by 37.6%, selling a total of 108,399 shares during the first quarter, leaving them with 180,044 shares worth approximately $13 million.
• Several analysts have increased their price targets for Edwards Lifesciences, with a consensus rating of "Moderate Buy" and an average target price of $85.71.
• Despite the sales by Natixis and other institutions, institutional investors own 79.46% of Edwards Lifesciences, reflecting substantial institutional interest in the company.

Natixis Advisors LLC decreased its position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 37.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 180,044 shares of the medical research company's stock after selling 108,399 shares during the quarter. Natixis Advisors LLC's holdings in Edwards Lifesciences were worth $13,050,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. North Star Asset Management Inc. grew its holdings in Edwards Lifesciences by 34.9% during the first quarter. North Star Asset Management Inc. now owns 47,564 shares of the medical research company's stock worth $3,447,000 after buying an additional 12,293 shares in the last quarter. Wellington Shields & Co. LLC grew its holdings in Edwards Lifesciences by 15.0% during the first quarter. Wellington Shields & Co. LLC now owns 1,150 shares of the medical research company's stock worth $83,000 after buying an additional 150 shares in the last quarter. First National Trust Co grew its holdings in Edwards Lifesciences by 4.9% during the first quarter. First National Trust Co now owns 3,704 shares of the medical research company's stock worth $268,000 after buying an additional 172 shares in the last quarter. XTX Topco Ltd grew its holdings in Edwards Lifesciences by 32.2% during the first quarter. XTX Topco Ltd now owns 27,622 shares of the medical research company's stock worth $2,002,000 after buying an additional 6,722 shares in the last quarter. Finally, S&CO Inc. grew its holdings in Edwards Lifesciences by 34.2% during the first quarter. S&CO Inc. now owns 82,797 shares of the medical research company's stock worth $6,001,000 after buying an additional 21,115 shares in the last quarter. Institutional investors own 79.46% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on EW shares. Canaccord Genuity Group upped their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the stock a "hold" rating in a report on Friday, July 25th. BTIG Research upgraded Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price target for the company in a report on Tuesday, July 29th. Truist Financial upped their price target on Edwards Lifesciences from $81.00 to $82.00 and gave the stock a "hold" rating in a report on Friday, July 25th. JPMorgan Chase & Co. upped their price target on Edwards Lifesciences from $80.00 to $85.00 and gave the stock a "neutral" rating in a report on Friday, July 25th. Finally, Mizuho upped their price target on Edwards Lifesciences from $87.00 to $95.00 and gave the stock an "outperform" rating in a report on Friday, July 25th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, thirteen have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $85.71.

Edwards Lifesciences Stock Down 0.0%

Shares of NYSE EW opened at $79.30 on Monday. Edwards Lifesciences Corporation has a one year low of $59.41 and a one year high of $83.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.45 and a quick ratio of 3.66. The business's fifty day moving average price is $76.91 and its 200-day moving average price is $73.85. The stock has a market capitalization of $46.52 billion, a PE ratio of 11.41, a P/E/G ratio of 3.84 and a beta of 1.08.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.25% and a net margin of 72.96%. The firm had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.49 billion. During the same quarter in the prior year, the firm earned $0.70 EPS. The business's revenue for the quarter was up 11.9% compared to the same quarter last year. On average, equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Activity

In related news, VP Daveen Chopra sold 1,500 shares of the stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $75.08, for a total transaction of $112,620.00. Following the sale, the vice president owned 33,496 shares of the company's stock, valued at approximately $2,514,879.68. This represents a 4.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction dated Friday, May 9th. The stock was sold at an average price of $74.40, for a total value of $837,000.00. Following the sale, the chief financial officer directly owned 41,098 shares in the company, valued at $3,057,691.20. This trade represents a 21.49% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,982 shares of company stock worth $2,193,425. 0.34% of the stock is owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.